Arena Pharmaceuticals (ARNA)
Q2 2012 Earnings Call
August 09, 2012 5:00 pm ET
Jack Lief - Chairman, Chief Executive Officer, President, Co-Founder, Chief Executive Officer of Aressa, President of Aressa, Chief Executive Officer of Brl, President of Brl, Director of Aressa and Director of Brl
Craig Michael Audet - Senior Vice President of Operations and Head of Global Regulatory Affairs
Robert E. Hoffman - Chief Financial Officer, Principal Accounting Officer and Vice President of FinanceAnalysts
Matthew Lowe - JP Morgan Chase & Co, Research Division
Alan Carr - Needham & Company, LLC, Research Division
Thomas Wei - Jefferies & Company, Inc., Research Division
Jason N. Butler - JMP Securities LLC, Research DivisionPresentationOperator
Good day, everyone, and welcome to Arena Pharmaceuticals' Second Quarter 2012 Conference Call. This call is being recorded. At this time, for opening remarks and introductions, I would like to turn the call over to Arena's Vice President, Investor Relations and Alliance Management, Ms. Cindy McGee. Cindy McGee, please go ahead.Cindy McGee
Welcome, and thank you for joining us. On today's call, we will review our second quarter financial results and provide a business update. Prepared remarks will be provided by Jack Lief, our President and Chief Executive Officer; Craig Audet, our Senior Vice President of Operations and Head of Global Regulatory Affairs; and Robert Hoffman, our Chief Financial Officer. Dominic Behan, our Chief Medical Officer, will also be available to address your questions.
During this conference call, we will make forward-looking and other statements about our views, including statements about BELVIQ or Lorcaserin and our drug candidates, including, with regard to efficacy, safety, potential plans and future activities and events, research, development and commercialization, the regulatory process and other statements that are not historical facts. Such statements may include the words plan, will, expect, believe, may, could, would or similar words. You are cautioned to not place undue reliance on these forward-looking statements, which are only predictions and reflect the company's beliefs, expectations and assumptions based on currently available information and speak only as of the time they are made. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Risks and uncertainties that could cause actual results to differ materially from those described in our forward-looking statements include: drug development, the regulatory process and commercialization are uncertain; data and other information related to drug and drug candidates may not be as expected, favorable or sufficient for further development or commercialization; the timing, results and costs of research and development; the regulatory process and commercialization and other risks identified in our SEC reports. For a discussion of these and other factors, please refer to the risk factors in our SEC filings.